Dallas Conference • April 8-9, 2016

The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences cover topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.

Welcome/Introduction• Mack Mitchell, MD, and Lawrence R. Schiller, MD

HCV: Resistance, DAA failures, and other difficult situations• Eric Lawitz, MD

HCV: Renal failure, advanced cirrhotics and liver cancer risk after cure• Norah A. Terrault, MD

Treatment options for HCV GT1 and GT3 patients -
the pros and cons of DAA class combinations• Paul Kwo, MD, Norah Terrault, MD, Eric Lawitz, MD and Fred Poordad, MD

HBV: Future development and novel mechanisms of action• Paul Kwo, MD

Sphincter of Oddi dysfunction• Paul R. Tarnasky, MD

Patient management update: Chronic constipation• Lawrence R. Schiller, MD

Manipulating the microbiome to treat IBS• Christopher Chang, MD, PhD

Eosinophilic esophagitis• Joel Richter, MD

Nonmedical therapeutic modalities for GERD: What's in the toolbox?• Ronnie Fass, MD

Refractory GERD: Residual reflux or something else?• Michael F. Vaezi, MD, PhD, MSc

Management of NAFLD/NASH: Diagnostic modalities and future treatment options• Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD

Management of alcoholic liver disease• Mack Mitchell, MD

Management of PBC, PSC, and autoimmune hepatitis • Fred Poordad, MD

Dilemmas in the management of ulcerative colitis in 2016• Stephen B. Hanauer, MD

Dilemmas in the management of Crohn's disease in 2016• Dario R. Sorrentino, MD, FRACP

Implementing the new IBD guidelines to improve patient outcomes• Themistocles Dassopoulos, MD